1CrystalGenomics, Inc.

OVERVIEWCRYSTALGENOMICS, INC.

January 2016

2CrystalGenomics, Inc.

To become a fully integrated biopharmaceutical company in Korea and expand internationally through collaborations and partnerships Vision

2000.07 Founded2003.09 Publication in Nature (article and cover based on platform technology)2006.01 IPO on KOSDAQ 2006.10 Established US subsidiary, CG Pharmaceuticals, Inc. for clinical development2012.06 Designated by the Korean government as one of the ‘KIPC’ certified companies2014.07 Designated by the Korean government as one of the ‘K-BrainPower’ companies2015.02 Obtained the NDA approval from MFDS for Acelex® in Korea (osteoarthritis)2015.09 Launch of Acelex® in Korea

History

Next generation NSAID, Acelex® for osteoarthritis (first-in-class) Novel antibiotic candidate for MRSA infection, CG400549 (first-in-class)Molecular-targeted cancer therapeutic, CG200745 (best-in-class)

Key Pipeline

CrystalGenomics is a commercial stage biopharmaceutical companywith innovative platform technologies dedicated in the discovery anddevelopment of novel pharmaceuticals in unmet medical need areas.

Corporate Overview

3CrystalGenomics, Inc.

Platform Technology Overview

Integration of in vitro experiments and in silico technology enables the company to streamline the drug discovery process from gene to drug.

Lead Discovery ( SCPTM )

SCPTM NMR

Virtual Screening In vitro Assay

SCPTM LibrarySCPTM Screening

Synchrotron, NMR

Structure Determination ( SPSTM )

AGTCTCAG

TargetSelection

Lead Optimization and Candidate Selection ( SDFTM )

In vivo Evaluation

DMPKToxicologyPharmacologyDDS

BiologicalEvaluations

Target Assays Cellular AssaysIn vitro DMPK

Drug Design &MediChem

SDFTM X-raySDFTM InformaticsParallel Synthesis

Pre-clinicalCandidate

Lead / TargetComplex

OR2

R3

ON

R1

IND-enabling Tox(CRO in EU,USA)

4CrystalGenomics, Inc.

CG Has Global Standard Drug Discovery Capabilities

Viagra ®

(sildenafil)

Cialis ®

(tadalafil)

Levitra ®(vardenafil)

CrystalGenomics was the first group to solve complex crystal structure of PDE5 using SPS™ approach: nature 425, 98-102 (2003).

5CrystalGenomics, Inc.

Disease Target Candidate Indication Phase I Ph II Ph III

1Pain & Inflammation Osteoarthritis (NSAID)

1Infectious Disease MRSA (super bug)

2Cancer MDS (liquid tumor)

2Cancer Pancreatic cancer

1Cancer AML (liquid tumor)

1CNS Alzheimer’s Disease, Parkinson’s Disease

2Metabolic Anemia

1. First-in-class , 2. Best-in-class

Novel R&D Pipeline

Therapeutic Area Indication Discovery Preclinical Ph I Ph II Ph III NDA

6CrystalGenomics, Inc.

Global Pain Therapeutics Market

Global Pain Market

$ 50 B

2012 2013 2014

GLOBAL 2,719 2,918 *2,699

KOREA 52 59 70

(Unit: in millions USD)

Celebrex® Sales

Global market size of pain therapeutics was valued at $ 50B (2011) Size of the NSAID market (including COX-2 inhibitors) ≈ $ 17.5B Rapid increase in the aging and obese population will lead to further growth

of the NSAID market

Patent expiry in US

7CrystalGenomics, Inc.

Huge Unmet Medical Needs in Pain Therapeutics Market

Classification Characteristics Efficacy GI Risk CV Risk

Traditional NSAID

- Inhibits both COX-1 and COX-2- Dosage: 2-4 times a day- PPI combination regimen

Moderate ~ High High Moderate ~

High

COX-2 Inhibitors

- COX-2 selective inhibition (less COX-1 inhibition)

- Etoricoxib (Merck) – once a day (30-120mg/day)High Low Moderate ~

High

- Celecoxib - once or twice a day (200 ~ 400mg/day)

Moderate~High

Low Moderate

Tissue-Specific COX-2 Inhibitor

(Acelex®)

- COX-2 selective inhibition (less COX-1 inhibition)

- “Tissue-selective” COX-2 inhibitor - Once a day 2mg dose

High LowNone

observed to date

8CrystalGenomics, Inc.

Acelex®, Tissue Selective NSAID for Osteoarthritis

Category Projected Advantages of Acelex

Efficacy • Quicker onset of relief from the signs and symptoms of OA over celecoxib.• Achieved superior PGA (Physicians Global Assessment) scores compared to celecoxib.

Dose • Only 2 mg/day dose, the lowest daily dose among all known NSAIDs.

Administration Frequency • Convenient once-a-day dosing regimen unlike most other NSAIDs.

Gastrointestinal Side Effects • Significantly improved GI safety in comparison with traditional NSAIDs on the market.

Cardiovascular Side Effects

• Acelex’s tissue-selective-COX2-inhibition mechanism is projected to provide a meaningful enhancement of cardiovascular safety over currently available NSAIDs.

< Acelex® 2mg Capsule >Tissue-Selective NSAID for the Relief of Signs Symptoms of Osteoarthritis (OA)

• Approved by the MFDS (Feb. 2015),• Launched in Korea by Dong-A ST (Sep. 2015)• Partnered with TR-Pharm for Turkey & MENA (Jan. 2016)

9CrystalGenomics, Inc.

Acelex®, Phase III Study Results

71.9% of subjects taking Acelex experienced improvement in signs and symptoms of osteoarthritis

*PGA (Physician’s Global Assessment ): Evaluation of the test subjects by the investigators (physicians)

Acelex showed SUPERIOR EFFICACY over celecoxib with statistical significance (p = 0.005)

Overall improvement of signs and symptoms of osteoarthritis in terms of PGA* scores at week 3

10CrystalGenomics, Inc.

Acelex®, Phase III Study Results

Acelex showed QUICKER ONSET OF RELIEF from osteoarthritis symptoms over celecoxib

Acelex showed statistically significant superiority over placebo at Week 3 (p=0.003), but celecoxib did NOT show statistically significant differentiation from placebo at Week 3 (p=0.069)

WOMAC Physical Function scores at Week 3

Acelex demonstrated non-inferior or better efficacy against celecoxib in all other efficacy endpoints including WOMAC-pain and –stiffness subscales at week-3 and week-6

11CrystalGenomics, Inc.

Acelex®, Rapid Increase in Domestic Sales

0

2,000

4,000

6,000

8,000

10,000

Qty. Ordered by Dong-A ST

Capsule Quantity

750,000 450,0001,500,000

10,500,000

Aug. 2015 Sep. 2015 Jan. 2016 Apr. 2016

No. of caps (thousands)

12CrystalGenomics, Inc.

Launch of 2 mgCapsule 2015

Generic Entry Block2026~2034

• Launch in Korea• Export or Out-Licensing

• Expansion of Acelex portfolio through development of combination products,incrementally modified products, new dosage forms, and additional indications.

• Goal is to maintain exclusive position up to 2026~2034 and maximize revenues.

Acelex®, Lifecycle Management Strategy

Strengthening of the Acelex brand name through launch of multiple products

13CrystalGenomics, Inc.

First-in-class, novel antibiotic that has demonstrated excellent efficacy againstMRSA, “Superbug” strains and, demonstrated superior in vitro efficacy overexisting blockbuster drugs including Pfizer’s $1.2 billion drug, Zyvox®

▪ MRSA killed 19,000 people in US, more than HIV (2009)

▪ ‘Europe 'losing' superbugs battle” - Over 25,000 people die in the EU every year of bacterial infections that are able to outsmart even the newest antibiotics (BBC News: April 2011)

▪ Zyvox® (Pfizer) – Global sales of USD 1.2B (2010) & USD 4M in Korea w/ 20%+ CAGR (2009)

▪ Global MRSA market will grow at a CAGR of 3.4% to reach USD 3.47B by 2019 (GlobalData: June 2012)

▪ CG400549 is potentially first-in-class antibiotic to treat MRSA and other multidrug resistant bacterial strains.

▪ Phase IIa skin infection study for POC completed (USA) – 100% of evaluable subjects had clinical cures by end of the study

▪ Both oral and intravenous formulations will be developed for oral/IV switchability

CG400549, Novel Antibiotic for MRSA in Ph II Development

14CrystalGenomics, Inc.

• Clinical studies conducted in the EU and US thus far• During the Ph 2a study conducted in the US, 100% clinically cure rate was achieved

Case 1

Case 2

Case 3

Screening ECE EOT TOC

*ECE : 48-72 hours after Day 1 *EOT : 10-14 days after Day 1 *TOC : 21-28 days after Day 1

CG400549, Novel Antibiotic for MRSA in Ph II Development

15CrystalGenomics, Inc.

Being developed as a potentially best-in-class drug with superior efficacy andsafety profiles than other HDAC inhibitors on the market or in development

CG200745, Best-in-Class Anti-Cancer Therapeutic

▪ CG200745 is a Histone deacetylase (HDAC) inhibitor being developed to combat various tumor types

▪ “There is growing evidence that HDACs are important agents for cancer therapy, and HDAC inhibitors bear great potential as anticancer drugs.”1

▪ POTENTIALLY BEST-IN-CLASSBased on preclinical and interim Ph 1 clinical data thus far, CG200745 is projected to have superior PK profile over other HDAC inhibitors (both approved & in development) as it has high level of exposure even at low doses

▪ SUPERB EFFICACY56% of all patients had stable disease from phase I studies which included variety of solid tumor patients

▪ Ph I Multiple Dose Study Completed (Korea); Ph Ib / II Ready for MDS and pancreatic cancer1 Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions (Cancer Drug Discovery and Development), 2006

16CrystalGenomics, Inc.

Korea Innovative Pharmaceutical Company Designation

CrystalGenomics was selected by the Korean Governmentas one of the ‘Korea Innovative Pharmaceutical Company’ (KIPC) on June 18, 2012.

KIPC is part of a recent initiative rolled out by the Korean Government where it pledged to nurture and support selected pharma and biotech companies to help them grow into global pharmaceutical companies by 2020.

CrystalGenomics ranked within the top 10 among all 43 KIPC designated companies.

Some of the key benefits includes: ▪ Favorable pricing & reimbursement benefits for novel

drugs▪ R&D and Financial support in research grants,

government subsidies, tax breaks, loans, etc.

17CrystalGenomics, Inc.

Fund Raisings

KSLSFKRW 100B

June 2014

January 2012

KRW 3 Billion Equity Financing

Global Pharmaceutical Industry Development Fund is KRW 100 billion fund established by the Ministry of Health and Welfare (MOHW) of Korea to promote globalization of the Korean pharmaceutical industry

Korea Seoul Life Science Fund is a KRW 100 billion, Government backed life science fund with private LPs and Hanwha VC & Oxford Bioscience as the two GPs

CG Raised KRW 26 Billion from Government backed Life Science Funds

Replenishment of cash reserves to fully support development of therapeutic programs

GPIDPKRW 100B

KRW 13 Billion Equity & Debt

FinancingInterVest

18CrystalGenomics, Inc.

Integrated Healthcare Company

API DP, Sales &Marketing

Analytical/Diagnostics

R&D

HWAIL PHARMANumber one in Korea in APIs

BTO BIOPHARMNew GMP facilities

with room for growth

SPL is one of the top bioanalyitcal service CROs in Korea

CG is a leading biopharmaceutical company in Korea

19CrystalGenomics, Inc. •19

•SBI BIOTECH CO., LTD.

Former & Current Alliance Partners

20CrystalGenomics, Inc.

CrystalGenomics, Inc.5th F. Bldg.A, Korea Bio Park700 Daewangpangyoro, Bundanggu,Seongnamsi, Gyeonggido 463-400Korea

CG Pharmaceuticals, Inc.5980 Horton Street, Suite 610Emeryville, CA 94608U.S.A.